|Articles|May 12, 2015
Dr. Shore Provides an Overview of Biomarkers in Prostate Cancer
Author(s)Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
Advertisement
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
“The field of biomarkers in prostate cancer is exploding exponentially, and it has been for some time now,” Shore says. “The challenge is that most of the biomarkers that are commercially available are not reimbursed and, some might argue, are truly not yet ready for primetime.”
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Inside the ‘Weird and Wacky’ Frontier of New Targeted Therapy for Lung Cancer
2
FDA Approves Imdelltra for Extensive-Stage Small Cell Lung Cancer
3
FDA Approves Hyrnuo in Some with Locally Advanced/Metastatic NSCLC
4
FDA Grants Fast Track Status to New Gastric Cancer Treatment
5
